<DOC>
	<DOCNO>NCT01776541</DOCNO>
	<brief_summary>Evaluate Safety , Tolerability Immune Response Adjuvanted H5N1 Cell Culture Derived Influenza Vaccine Adult Subjects .</brief_summary>
	<brief_title>Safety Immunogenicity Two Doses H5N1 Influenza Vaccine Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy adult subject 18 64 year age , 2 . Individuals willing provide write informed consent , 3 . Individuals good health , 4 . Individuals willing allow serum sample store beyond study period . 1 . Individuals able understand follow study procedure , 2 . History significant illness , 3 . History chronic medical condition progressive disease , 4 . Presence medically significant cancer , 5 . Known suspected impairment/alteration immune function , 6 . Presence progressive severe neurologic disorder , 7 . Presence bleed disorder condition prolongs bleed time , 8 . History allergy vaccine component , 9 . Receipt investigational product within 30 day prior entry study , 10 . History previous H5N1 vaccination , 11 . Receipt type seasonal vaccination within 2 month prior entry study , 12 . Receipt vaccine within 2 week prior entry study 13 . Body temperature ≥38°C.0 ( ≥100.4° F ) and/or acute illness within 3 day intend study vaccination , 14 . Pregnant breast feeding , 15 . Females childbearing potential refusing use acceptable method birth control , 16 . Body mass index ( BMI ) ≥ 35 kg/m2 , 17 . History drug alcohol abuse , 18 . Any planned surgery study period , 19 . Individuals conduct study immediate family member , 20 . Individuals behavioral cognitive impairment psychiatric disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Influenza , Pandemic , H5N1 , Adults</keyword>
</DOC>